Japan's Eisai won a crucial patent case in the U.S. with a judge's ruling that Teva and Dr. Reddy's were violating its patent on Aciphex, a stomach ulcer medicine that is Eisai's second biggest seller bringing in 26 percent of its revenue. With analysts betting that Eisai would lose the case, its stock roared up 13 percent on the news - its biggest gain in six years. Teva, for its part, plans to appeal. But the analysts say now that another ruling isn't expected for about two years, guaranteeing a significant amount of continued revenue for the drug company.
- here's the report for Haaretz